Publikasi Scopus 2010 s/d 2022

Afiatin, Khoe L.C., Kristin E., Masytoh L.S., Herlinawaty E., Werayingyong P., Nadjib M., Sastroasmoro S., Teerawattananon Y.
57194228502;56586245200;6504458442;57194227773;57194229356;57042584300;24401623600;6507794136;57193358558;
Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia
2017
PLoS ONE
12
5
e0177436
32
Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia; Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Jogjakarta, Indonesia; Centre for Health Financing and Security, Ministry of Health, Jakarta, Indonesia; Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangkok, Thailand; Indonesian Health Technology Assessment Committee, Jakarta, Indonesia
Afiatin, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia; Khoe, L.C., Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kristin, E., Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Jogjakarta, Indonesia; Masytoh, L.S., Centre for Health Financing and Security, Ministry of Health, Jakarta, Indonesia; Herlinawaty, E., Centre for Health Financing and Security, Ministry of Health, Jakarta, Indonesia; Werayingyong, P., Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangkok, Thailand; Nadjib, M., Indonesian Health Technology Assessment Committee, Jakarta, Indonesia; Sastroasmoro, S., Indonesian Health Technology Assessment Committee, Jakarta, Indonesia; Teerawattananon, Y., Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangkok, Thailand
Objectives: This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD) in Indonesia. Methods: A Markov model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Three policy options were compared, i.e., the PD-first policy, HD-first policy, and supportive care. Results: The PD-first policy for ESRD patients resulted in 5.93 life years, equal to the HD-first policy, with a slightly higher QALY gained (4.40 vs 4.34). The total lifetime cost for a patient under the PD-first policy is around 700 million IDR, which is lower than the cost under the HD-first policy, i.e. 735 million IDR per patient. Compared to supportive care, the incremental cost-effectiveness ratio of the PD-first policy is 193 million IDR per QALY, while the HD-first policy resulted in 207 million IDR per QALY. Budget impact analysis indicated that the required budget for the PD-first policy is 43 trillion IDR for 53% coverage and 75 trillion IDR for 100% coverage in five years, which is less than the HD-first policy, i.e. 88 trillion IDR and 166 trillion IDR. Conclusions: The PD-first policy was found to be more cost-effective compared to the HD-first policy. Budget impact analysis provided evidence on the enormous financial burden for the country if the current practice, where HD dominates PD, continues for the next five years. © 2017 Afiatin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
adult; Article; budget; cost benefit analysis; cost effectiveness analysis; economic evaluation; end stage renal disease; health care access; health care policy; health insurance; hemodialysis; human; Indonesia; major clinical study; peritoneal dialysis; quality adjusted life year; treatment planning; economics; health care policy; hemodialysis; insurance; Kidney Failure, Chronic; Markov chain; Cost-Benefit Analysis; Health Policy; Humans; Indonesia; Kidney Failure, Chronic; Markov Chains; Renal Dialysis; Universal Coverage
Bill and Melinda Gates Foundation; Rockefeller Foundation; Ministerio de Sanidad, Consumo y Bienestar Social; Department for International Development, UK Government
This work received funding support from the state budget from the Ministry of Health, Indonesia and the Australian Indonesian Partnership for Health Systems Strengthening (AIPHSS) under the Department of Foreign Affairs Trade, Australia. Technical assistance from the Health Intervention and Technology Assessment Program (HITAP) International Unit was supported by International Decision Support Ini
Public Library of Science
19326203
28545094
Article
Q1
1164
3497